These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 7052285)
1. Clinical and pharmacokinetic studies on the alpha- and beta-blocking drug labetalol. Kanto J; Allonen H; Lehtonen A; Mäntylä R; Pakkanen A Ther Drug Monit; 1980; 2(2):145. PubMed ID: 7052285 [No Abstract] [Full Text] [Related]
2. Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. Elliott HL; Meredith PA; Sumner DJ; Reid JL Br J Clin Pharmacol; 1984 May; 17(5):573-8. PubMed ID: 6145441 [TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of labetalol. McNeil JJ; Louis WJ Clin Pharmacokinet; 1984; 9(2):157-67. PubMed ID: 6370541 [TBL] [Abstract][Full Text] [Related]
4. Effect of food on the bioavailability of labetalol. Mäntylä R; Allonen H; Kanto J; Kleimola T; Sellman R Br J Clin Pharmacol; 1980 Apr; 9(4):435-7. PubMed ID: 7378263 [No Abstract] [Full Text] [Related]
5. Bioavailability of labetalol increases with age. Kelly JG; McGarry K; O'Malley K; O'Brien ET Br J Clin Pharmacol; 1982 Aug; 14(2):304-5. PubMed ID: 7104187 [TBL] [Abstract][Full Text] [Related]
6. Cimetidine and bioavailability of labetalol. Daneshmend TK; Roberts CJ Lancet; 1981 Mar; 1(8219):565. PubMed ID: 6111669 [No Abstract] [Full Text] [Related]
7. Pharmacokinetics of labetalol in healthy volunteers. Kanto J; Allonen H; Kleimola T; Mäntylä R Int J Clin Pharmacol Ther Toxicol; 1981 Jan; 19(1):41-4. PubMed ID: 7203731 [TBL] [Abstract][Full Text] [Related]
8. The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. Daneshmend TK; Roberts CJ Br J Clin Pharmacol; 1982 Jul; 14(1):73-8. PubMed ID: 7104169 [TBL] [Abstract][Full Text] [Related]
9. Decreased first-pass metabolism of labetalol in chronic liver disease. Homeida M; Jackson L; Roberts CJ Br Med J; 1978 Oct; 2(6144):1048-50. PubMed ID: 709214 [TBL] [Abstract][Full Text] [Related]
10. Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension. Louis WJ; Christophidis N; Brignell M; Vijayasekaran V; McNeil J; Vajda FJ Aust N Z J Med; 1978 Dec; 8(6):602-9. PubMed ID: 285681 [No Abstract] [Full Text] [Related]
11. Elimination kinetics of labetalol in severe renal failure. Wood AJ; Ferry DG; Bailey RR Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):81S-86S. PubMed ID: 7093103 [TBL] [Abstract][Full Text] [Related]
12. Pharmacology of combined alpha-beta-blockade. I. Louis WJ; McNeil JJ; Drummer OH Drugs; 1984; 28 Suppl 2():16-34. PubMed ID: 6151889 [TBL] [Abstract][Full Text] [Related]
14. Interaction of clonidine and labetalol in hypertension. Lilja M Acta Med Scand; 1983; 214(2):119-24. PubMed ID: 6624543 [TBL] [Abstract][Full Text] [Related]
16. The metabolism of labetalol in animals and man. Hopkins R; Martin LE; Bland R Biochem Soc Trans; 1976; 4(4):726-9. PubMed ID: 1001750 [No Abstract] [Full Text] [Related]
17. Labetalol. Current research and therapeutic status. Wallin JD; O'Neill WM Arch Intern Med; 1983 Mar; 143(3):485-90. PubMed ID: 6338850 [TBL] [Abstract][Full Text] [Related]
18. Labetalol. Carter BL Drug Intell Clin Pharm; 1983 Oct; 17(10):704-12. PubMed ID: 6354658 [TBL] [Abstract][Full Text] [Related]
19. The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. Daneshmend TK; Roberts CJ Br J Clin Pharmacol; 1984 Sep; 18(3):393-400. PubMed ID: 6487478 [TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalol. Frishman W; Halprin S Am Heart J; 1979 Nov; 98(5):660-5. PubMed ID: 386753 [No Abstract] [Full Text] [Related] [Next] [New Search]